EUVIMEDEUVIMED entdecken
Crossref

Chimeric antigen receptor T-cell therapy in multiple myeloma in 2026: approved indications, long-term outcomes, toxicity, sequencing, and emerging platforms: a narrative review

Wojciech Maciej Legiec, David H. Vesole, Artur Jurczyszyn

Acta Haematologica Polonica · 29.10.2026 · 57 (5) · 380-389

DOI: 10.5603/ahp.112557 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Haematologica Polonica, online erschienen am 29.10.2026. Verfasst von Wojciech Maciej Legiec und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Legiec, W. M., Vesole, D. H., & Jurczyszyn, A. (2026). Chimeric antigen receptor T-cell therapy in multiple myeloma in 2026: approved indications, long-term outcomes, toxicity, sequencing, and emerging platforms: a narrative review. Acta Haematologica Polonica, 57(5), 380-389. https://doi.org/10.5603/ahp.112557

Vancouver

Legiec WM, Vesole DH, Jurczyszyn A. Chimeric antigen receptor T-cell therapy in multiple myeloma in 2026: approved indications, long-term outcomes, toxicity, sequencing, and emerging platforms: a narrative review. Acta Haematologica Polonica. 2026;57(5):380-389. doi:10.5603/ahp.112557

BibTeX
@article{Legiec2026,
  author = {Legiec, Wojciech Maciej and Vesole, David H. and Jurczyszyn, Artur},
  title = {Chimeric antigen receptor T-cell therapy in multiple myeloma in 2026: approved indications, long-term outcomes, toxicity, sequencing, and emerging platforms: a narrative review},
  journal = {Acta Haematologica Polonica},
  year = {2026},
  volume = {57},
  number = {5},
  pages = {380--389},
  doi = {10.5603/ahp.112557}
}
Kostenlos starten →